Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „upadacitinib“
Suchtreffer
Begriffe & Kennungen
Rinvoq · 4.5 · 13 metabolite for atorvastatin). Administration of multiple 45 mg once daily doses of upadacitinib to healthy
Eintrag öffnenRinvoq · 4.5 · Administration of multiple 30 mg or 45 mg once daily doses of upadacitinib tablets to healthy subjects had a l
Eintrag öffnenRinvoq · 4.5 · Administration of multiple 30 mg or 45 mg once daily doses of upadacitinib to healthy subjects had a limited e
Eintrag öffnenRinvoq · 4.5 · Potential for other medicinal products to affect the pharmacokinetics of upadacitinib
Eintrag öffnenRinvoq · 4.5 · Potential for other medicinal products to affect the pharmacokinetics of upadacitinib
Eintrag öffnenRinvoq · 4.5 · Potential for upadacitinib to affect the pharmacokinetics of other medicinal products
Eintrag öffnenRinvoq · 4.5 · Potential for upadacitinib to affect the pharmacokinetics of other medicinal products
Eintrag öffnenRinvoq · 4.5 · Upadacitinib exposure is decreased when co-administered with strong CYP3A4 inducers (such as rifampin and phen
Eintrag öffnenRinvoq · 4.5 · Upadacitinib exposure is decreased when co-administered with strong CYP3A4 inducers (such as rifampin and phen
Eintrag öffnenRinvoq · 4.5 · Upadacitinib exposure is increased when co-administered with strong CYP3A4 inhibitors (such as ketoconazole, i
Eintrag öffnenRinvoq · 4.5 · Upadacitinib exposure is increased when co-administered with strong CYP3A4 inhibitors (such as ketoconazole, i
Eintrag öffnenRinvoq · 4.5 · Upadacitinib has no relevant effects on plasma exposures of ethinyl estradiol, levonorgestrel, methotrexate, o
Eintrag öffnenRinvoq · 4.5 · Upadacitinib has no relevant effects on plasma exposures of ethinyl estradiol, levonorgestrel, methotrexate, o
Eintrag öffnenRinvoq · 4.5 · Upadacitinib is metabolised mainly by CYP3A4. Therefore, upadacitinib plasma exposures can be affected by medi
Eintrag öffnenRinvoq · 4.5 · Upadacitinib is metabolised mainly by CYP3A4. Therefore, upadacitinib plasma exposures can be affected by medi
Eintrag öffnenRinvoq · 4.8 · 19 through week 260 for the upadacitinib 15 mg and 30 mg groups was 1.5 and 1.9 events per 100 patient-years,
Eintrag öffnenRinvoq · 4.8 · 21 • Total cholesterol ≥ 5.17 mmol/L (200 mg/dL): 49% vs. 11%, in the upadacitinib 45 mg and placebo groups, r
Eintrag öffnenRinvoq · 4.8 · 22 section 4.2). No notable mean changes of lymphocyte counts were observed during upadacitinib treatment over
Eintrag öffnenRinvoq · 4.8 · 75 term rate of opportunistic infections for the upadacitinib 15 mg group across all five Phase 3 clinical stu
Eintrag öffnenRinvoq · 4.8 · 78 maintenance study, the frequency of serious infection over 52 weeks in the upadacitinib 15 mg and 30 mg gro
Eintrag öffnen